Skip to content
Review

Targeting the Epigenetic–Immune Axis in Acute Myeloid Leukemia: Current Advances and Future Directions

Sep 2026 · Current Oncology Reports · Vol 28 · 0 citations · 111 references
Medicine

TL;DR

Ep epigenetic dysregulation is highlighted as both a fundamental driver of leukemogenesis and a clinically actionable therapeutic interface that may enable more rational treatment sequencing and personalized AML management.

View source

Similar papers

Review Open access Oct 2026

Epigenetic and Epitranscriptomic Regulation of Immune Checkpoint Response in Hepatocellular Carcinoma: Mechanisms, Therapeutic Targeting, and Translational Challenges.

Immune checkpoint inhibitors (ICIs) have reshaped systemic therapy for hepatocellular carcinoma (HCC), but durable benefit remains limited to a subset of patients because of tumor-intrinsic and microenvironmental mechanisms of immune resistance. Canonical epigenetic and epitranscriptomic alterations, including DNA meth...

Ya-Fei Zhi, Yan Guo, Hui-Fang Wei et al. · 0 citations
Review Open access Sep 2026

Epigenetic deregulation in adult gliomas: A key driver of molecular heterogeneity and precision oncology.

Key epigenetic mechanisms, including global DNA hypomethylation, promoter CpG island hypermethylation, histone acetylation and methylation and their effects on genome stability, transcriptional regulation, stemness, immune modulation, metabolic reprogramming, and therapeutic resistance are discussed.

Elifcan Gezer, Hamed Charkhian, Ş. Tunçer · 0 citations
Review Open access 2026

Transcriptional Control as a Therapeutic Strategy in Acute Myeloid Leukemia

: Acute myeloid leukemia (AML) is driven by dysregulated transcription factors (TFs) that disrupt hematopoietic differentiation, promote leukemic self-renewal, and confer therapy resistance. Key TFs including C/EBP α , PU.1, RUNX1, GATA2, EVI1, PML-RAR α fusion protein, p53, c-Myc and ERG are altered through mutations,...

Annisa Nurul Ilmi, Rudy Agung Nugroho, Sendy Junedi et al. · 0 citations
Review Open access Sep 2026

HDAC inhibitors in cancer therapy: sensitization mechanisms, combination strategies, and translational challenges

Histone deacetylases (HDACs) are key regulators of chromatin architecture and gene expression, and their dysregulation is closely linked to tumorigenesis, making them attractive targets for cancer therapy. Histone deacetylase inhibitors (HDACis) exert broad antitumor effects by modulating both epigenetic and non-epigen...

Kun Liu, Xiang Zhao, Jia-Hui Liu et al. · 0 citations
Review Open access Sep 2026

The Epigenetic Architecture of Classical Hodgkin Lymphoma: Lineage Erasure, Immune Escape, and Therapeutic Reprogramming

Classical Hodgkin lymphoma (cHL) is distinguished by a rare population of Hodgkin and Reed–Sternberg (HRS) cells that has largely extinguished its germinal center (GC) B-cell identity while maintaining survival, immune escape, and dependence on a highly organized tumor microenvironment (TME). This narrative review exam...

Matei Seleusan, D. Cenariu, A. Țigu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.